Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can't wait to see BC no longer being part of the equation. $LIBE GLTA
I'm back too. I've been lurking. Waiting for something to happen here. Here's hoping this pans out... This time. : )
When did we find out Sean Combs (Diddy) was an investor? I missed that piece. Is that confirmed?
Yeah thanks for the great reply.
Great reply. I know it's not the end. I just hate losing the power of multiplication. I'll have load again to get back to where I was. I still have faith in the mission and the product.
Here's to hoping RDGL does too.
The price is going to go down after the RS. Historically that's why I experience with RS. It'll be eight times the value for the first day for a little bit. Then it's start to drop sharply. Hope I'm wrong, but don't think I am.
You're right, but the power of my position when and if the PPS goes up is diminished, unless I want to load again. 1mil x $1 > 200k x $1.
Great we get an RS. Doesn't wipe out shareholders, but sure as hell reduces their positions. I'm pretty upset.... So for us to be rewarded we have to buy back in to get our positions back. Then hope it doesn't happen again. Maybe I am not seeing the upside to today's news? Any thoughts or insights are welcome.
A friend of mine has a dog with cancer. They are in MO. I sent them the clinical trials link. Here's hoping IsoPet can help their dog. GO $RDGL! I'll update if they try to get into the trial and give progress updates after they get in.
Here was the response from Vivos on the Dart treatment I found recently.
Me: I recently found this. How does this affect things? Are you all worried about something like this getting to market and human trials first? I know it is a different isotope. Can you tell me how this differs from RadioGel? Thanks and keep up the amazing with guys.
https://bit.ly/2BoUYG0
Vivos: Hi William. Quite different technology than ours. Alpha packs a big punch, but can also do lots of critical damage to adjacent cells. This may have results fighting a blood cancer. Using term minimally invasive here is a total stretch of the truth.
Tumors are still best treated with a Beta Emitter such as our Yttrium-90. If it’s one thing Dr. Korenko knows more than most is the various type of isotopes, their safety, and what they are useful for.
Merry Christmas.
Thanks. Not trying to shake the tree or bash here. Just wanted to get info in relation to this. I just found it. Great reply.
I don't have a lot of free time and I just found this. Thanks for quickly highlighting the difference / advantage. I have not even checked on IHUB or my stock apps. I have that much faith in RDGL and my shares here. :) Thought I would look today.
I thought it said they inject into the tumor and it breaks down too one sec... Nope. You are right. It does leave them in the body.
The darts need to be maintained embedded in the surface for at least two weeks to give the alpha particles time to destroy the cancer. In the case of a cancer of an internal organ, the darts can be left inside forever because they are biocompatible, Sofer explained.
Me too. Me too. I would be very happy with .41. I am loaded. Ready to roll when and if we do.
LOL. Well others can say what they want. I am just being objective and just found this info. Not bashing RDGL. Would love to get others thoughts on it and how it might affect RDGL.
Clearly they started human trials in 2017.
Y90 vs Radium-224? Pros cons?
They are getting multi-million in funding from VC and angel investors.
The startup already has a production facility in Israel and is building a new one in Massachusetts, with more to come in Europe and Japan, said Sofer.
Meanwhile the firm has started two additional clinical trials in Italy, one of them at La Sapienza, in Rome, and has raised some $29 million in a third funding round from various angels and VCs, Medison Pharma, several investors from the US and Europe, Shavit Capital – an Israeli investing firm focusing on late-stage investments, crowdfunding platform OurCrowd, and billionaires like Ronald Cohen, Alan Patricof, plus the previous investors, Sofer said.
The Tel Aviv-based company employs 25 people in Israel, and will soon hire 10-15 more, said Sofer.
Asked about future developments of the company’s products, Sofer said Alpha Tau Medical is now integrating its therapy with ultrasound and CT-guided applicators to treat lung, pancreatic and liver cancers by inserting the alpha-emitting device while at the same time “putting a fiducial marker or taking a biopsy.” Mass production is the firm’s goal, he said, adding that it was going to improve its results by combining its technology with different immune therapies.
“We feel that it is really breakthrough and game-changing in the field of oncology,” he said. “We are really seeing a miracle.”
I am big fan of RDGL. This seems to be very similar, but with Radium-224 instead of y90.
https://www.timesofisrael.com/anti-tumor-dart-could-point-the-way-to-new-arsenal-in-battle-against-cancer/
Thanks I have not been checking the boards. Holding and waiting.
Sounds very familiar and it's already in human trials. Thoughts?
----------
Israeli company claims it has created new technology that can destroy cancerous tumors.
...
The technology called Diffusing Alpha-emitters Radiation Therapy, or DaRT, uses a needle to inject tumors with a radioactive seed that releases a high-energy dose of radiation that destroys the tumor. The healthy tissue surrounding the tumors is left unharmed.
...
"In the process of decay, Radium-224 releases its short-lived Alpha-emitting atoms into the tumor," according to the company's website. "By diffusion and convection, these atoms disperse to a therapeutically significant range of several millimeters, delivering a high dose of radiation inside the tumor."
https://bit.ly/2BoUYG0
The CEO and CFO just form-4'ed more shares then anyone in the past several years. Something is coming, they know it. IMO.
Insider Actions for Vivos Inc.
10/24/2018 Michael K. Korenko CEO AND PRESIDENT 28,197,136
Award at $0 per share. 0
10/24/2018 Leonard Bruce Jolliff CHIEF FINANCIAL OFFICER 10,465,426
Award at $0 per share. 0
10/10/2018 Michael K. Korenko CEO AND PRESIDENT 3,600,000
Award at $0 per share. 0
11/20/2017 Michael K. Korenko CEO AND PRESIDENT 280,000
Acquisition at $0.03 per share. 8,400
05/16/2017 Michael K. Korenko CEO AND PRESIDENT 100,000
Acquisition at $0.1 per share. 10,000
01/17/2017 Michael K. Korenko CEO AND PRESIDENT 223,679
Acquisition at $0.15 per share. 33,551
01/13/2017 Michael K. Korenko CEO AND PRESIDENT 476,321
Acquisition at $0.15 per share. 71,448
10/05/2015 Carlton M. Cadwell Director 6,600,000
0
08/14/2015 Carlton M. Cadwell Director 400,000
Award at $0 per share. 0
04/10/2015 Carlton M. Cadwell Director 353,333
Award at $0 per share. 0
02/25/2015 James C. Katzaroff CEO; Director 1,000,000
Acquisition at $0 per share. 0
02/25/2015 Carlton M. Cadwell Director 1,040,000
Award at $0 per share. 0
I feel we are past step one, but for humans I would be okay holding a couple years. At least a core position. After taking some profit with IsoPet revenue next year. I should of pulled my principle at .04 and rode with free shares, but I am still feeling good about RDGL over the next 3-5 years. I'll continue loading where it makes sense. Though I think we'll see a win in 2019 for sure. Also, Right to Try gives them another way to speed up the process possibly.
RICHLAND, WA / ACCESSWIRE / September 7, 2017 / Advanced Medical Isotope Corporation ("AMI") (OTC PINK: ADMD), a late stage radiation oncology focused medical device company, submitted a 233-page request to the Food and Drug Administration (FDA) for a pre-submission meeting to review the test plans for the remaining pre-clinical testing and to request a De Novo path for its pre-market application. A De Novo path is faster and less onerous than standard Premarket Approval pathway.
The FDA was very helpful, providing 14 pages of comments prior to the meeting with further insights and clarifications during the meeting from the 12 participants. Their observations and recommendations are being incorporated in the Company's test plans. The bench top (in vitro) testing will begin late September. The detailed animal study plans will be sent back to the FDA for a final review. It is important that the FDA agrees with the plans before they are conducted to increase the probability that the data will be accepted as adequate to allow the first clinical studies of Y-90 RadioGel™ in humans. The FDA also agreed to follow-up communications with their experts on specific topics. This is beneficial to ensure that we are totally aligned on the most complex subjects.
In previous written feedback to ADMD, the FDA recommended Premarket Approval (PMA) as a Class III device. In this meeting, we requested consideration for a De Novo reclassification as a Class II device based on the risks associated with the device. A De Novo path is faster and less onerous than a PMA. The FDA responded that they would need to first see the data from the pre-clinical testing so they could balance the therapeutic value versus the risks. We interpret this as encouraging since they did not refer to a PMA path and we expect the test data will demonstrate that RadioGel™ is a low to moderate risk device with clear therapeutic benefits.
Just dropping this here....
University of Missouri IsoPet Trial
The purpose of this study is to evaluate the dosimetry, toxicity and efficacy of IsoPet™ 90 Yttrium phosphate nanoparticles in dogs with spontaneous soft tissue sarcomas. This is a one month study with monthly recheck visits thereafter for the first six months.
Criteria:
Soft tissue sarcoma diagnosed by cytology or histopathology
Tumor must measure at least 2 cm in longest dimension at enrollment-tumor must be present
CBC, chemistry panel, UA, (adequate bone marrow function, liver and renal function), thoracic radiographs, +/- abdominal and/or tumor imaging at first visit
No evidence of metastasis on thoracic radiographs
Mass must be superficial and accessible to brachytherapy
Patient must weigh at least 10 kg
Therapy:
One or more needles evenly placed throughout tumor for brachytherapy (IsoPet™) injections.
CT/PET scan to follow IsoPet™ injections, followed by 3-5 day stay in radiation isolation.
Weekly recheck visits required at VHC with CBC, chemistry panel, urinalysis at week 2 and 4.
Repeat CT scan at week 2 visit.
Monthly visits after week 4.
Benefit:
Owner to cover costs associated with initial visit and staging (CBC, chemistry panel, urinalysis, thoracic radiographs, +/- abdominal US and/or tumor imaging).
Once enrolled study covers costs associated with brachytherapy (IsoPet™ injections, CT/PET, anesthesia, hospitalization, pain medications, blood work, office visits for one month post injection.
Owner may incur additional expenses (medications, cytology’s, etc.) depending pet’s needs.
Contact Faculty Person: Dr. Charlie Maitz
Moose updates, not sure if they were posted already.
https://www.facebook.com/1839463746091221/posts/1905567782814150/
https://www.facebook.com/1839463746091221/posts/1905617252809203/
I just love seeing the results. This is why I'm long here. Just look at him 5 days after to 10 days. This is just amazing stuff guys. $RDGL
https://www.facebook.com/Mooses-Journey-Fighting-Canine-Soft-Tissue-Sarcoma-1839463746091221/
Wonder if we could of helped Duke out??
https://theirfo.com/2018/07/23/duke-the-mascot-of-bushs-baked-beans-loses-battle-with-cancer/
That is what my group is asking. What industry are they going to target? Could it be another BIOTECH company since George is already working with one as an advisor to RDGL? I just want to know the direction they are going to go after they are done cleaning the shell.
Yes sir. I am liking it.
Look at the accumulation for today! Climbing despite the flippers.
TOS Chart
We need a fat green candle to close this day out. Come on. :)
I certainly hope so. :)
I thought he bought 10 million? I'm new to form 4. Trying to break it down.
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned1.Title of Security
(Instr. 3)2. Trans. Date2A. Deemed Execution Date, if any3. Trans. Code
(Instr. 8)4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)7. Nature of Indirect Beneficial Ownership (Instr. 4)CodeVAmount(A) or (D)PriceCommon Stock 10/24/2018 A 10465426 A (1)13805760 D
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)1. Title of Derivate Security
(Instr. 3)2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)8. Price of Derivative Security
(Instr. 5)9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of SharesWarrants $0.01 10/24/2018 A 5232713 10/24/2018 10/24/2020 Common Stock 5232713 (1)5232713 D
Options $0.014 10/24/2018 A 24360455 10/24/2018 10/24/2025 Common Stock 24360455 (2)29593168 D
Explanation of Responses:(1) Represents securities issued in lieu of cash owed to the Reporting Person for past services rendered to the Issuer in his capacity as Chief Financial Officer.(2) Represents securities issued to the Reporting Person as a bonus for services rendered to the Issuer in his capacity as Chief Financial Officer.
The $LIBE and Peppermint Jim's love song. PJ's was to hot and spicy for BC. ????????
From what I heard SOS fillings can be an early sign of a reverse merger coming.
What is going on here? Not going to complain, but I can't tell why we are climbing. Go $LIBE?
That has been my thoughts.
Donated $20 to Stand Up to Cancer, but that donation page isn't for her. She will have a GoFundMe up soon.
From the FAQ. See the bottom of post.
My questions are this:
Are we phase one approved with FDA?
By be in correct clinical trials, does that require already being in human trials or will the pet trials qualify?
--------
Who qualifies for Right to Try?
To be eligible for Right to Try, a patient must meet the following conditions:
Be diagnosed with a life-threatening disease or condition;Have exhausted approved treatment options;Be unable to participate in a clinical trial involving the eligible investigational drug, as certified by a doctor, who is in good standing with her licensing organization and will not be compensated directly by the manufacturer for so certifying; andGive written informed consentregarding the risks associated with taking the investigational treatment.
What is a life-threatening disease or condition?
Federal law defines a life-threatening disease or condition as: “Diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted” (21 CFR 312.81).
What drugs or treatments qualify for Right to Try?
The treatments available under the law must meet the following conditions:
Have completed an FDA-approved Phase 1 clinical trial;
Be in an active clinical trial intended to form the basis of an application for approval or be the subject of an application for approval that has been filed with the FDA;
and Be in ongoing active development or production and not discontinued by the manufacturer or placed on clinical hold.
First thing I'm doing once I get home.
Damn right. Great way to end the week. GO $RDGL!!!